The Pharmacology of Monoclonal Antibodies

  • Martin Rosenberg
  • Gordon P. Moore

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 113)

Table of contents

  1. Front Matter
    Pages I-XXI
  2. Human Monoclonal Antibodies

    1. Front Matter
      Pages 1-1
    2. J. W. Larrick, R. Balint
      Pages 23-48
  3. Genetically Engineered Monoclonal Antibodies

    1. Front Matter
      Pages 103-103
    2. G. E. Mark, E. A. Padlan
      Pages 105-134
  4. MAb Conjugates and Fusions

    1. Front Matter
      Pages 147-147
    2. S. H. Pincus
      Pages 149-178
    3. A. Traunecker, K. Karjalainen
      Pages 199-206
  5. Combinatorial Libraries

    1. Front Matter
      Pages 207-207
    2. K. D. Janda, Chen Y.-C. Jack
      Pages 209-241
    3. C. F. Barbas III
      Pages 243-266
  6. Expression of MAbs/MAb Fragments

    1. Front Matter
      Pages 267-267
    2. A. Plückthun
      Pages 269-315
  7. Medical Applications

    1. Front Matter
      Pages 345-345

About this book

Introduction

It has been almost 20 years since the discovery by Kohler and Milstein of the technology to produce monoclonal antibodies (MAbs), a discovery that promised revolutionary changes in research, clinical diagnosis and human therapy. From today's perspective, it is fair to conclude that this promise has been realized in two areas of the three. As research tools, MAbs have been invaluable: their ability to selectively bind and localize specific antigens, detect and identify new ligands and their receptors, and agonize and/or antagonize specific molecular interactions continues to provide a useful and enabling technology to basic research endeavors. Similarly, MAbs have demonstrated enormous practical impact as diagnostic tools. Recent advances in clinical diagnostic medicine continue to rely heavily on the use of MAb-based reagents for detecting and localizing antigens of clinical import. In contrast, however, MAbs have not proven to have major impact on human disease therapy. With the single exception of an immunosup­ pressive MAb against the T-cell antigen, CD3, MAbs have as yet found few meaningful applications as therapeutic agents. During the 1980s, a set of technologies to clone, modify and express genes encoding MAbs was developed. These breakthroughs permitted MAbs to be genetically engineered which consequently gave them the potential to greatly enhance their therapeutic utility as well as significantly expand their research and diagnostic applications. New MAbs, fragments of MAbs, bispecific MAbs, single-chain MAbs, and fusions of MAbs with other gene products became available for study.

Keywords

Combinatorial Cloning Klonung Monoclonal Antibodies Monoklonaler Antikörper Polymerase Chain Reaction

Editors and affiliations

  • Martin Rosenberg
    • 1
  • Gordon P. Moore
    • 2
  1. 1.Biopharmaceuticals Smith Kline Beecham PharmaceuticalsKing of PrussiaUSA
  2. 2.Department of Molecular GeneticsSmith Kline Beecham PharmaceuticalsKing of PrussiaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-78432-3
  • Copyright Information Springer-Verlag Berlin Heidelberg 1994
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-78434-7
  • Online ISBN 978-3-642-78432-3
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • About this book
Industry Sectors
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods
Pharma